title: [A meta-analysis of liver lesions in hepatitis B patients undergoing anti-tuberculosis therapy].
abstract: OBJECTIVE
  To evaluate the effect of different immune status on the incidence of hepatic lesions in patients with hepatitis B virus (HBV) infection undergoing anti-tuberculosis therapy.
  
  
  METHODS
  The PubMed (1966-2013), Embase (1966-2013), Wanfang (1998-2013), Chinese National Knowledge Infrastructure (CNKI; 1997-2013), and Chinese Biomedical (CBMdisc; 1860-2013) literature databases were searched for case-control studies of hepatic lesions in patients undergoing anti-tuberculosis therapy with or without concomitant HBV infection. The HBV patients were divided into subgroups according to hepatitis B e antigen (HBeAg) positivity or negativity, all members of the control group were HBsAg⁻. The data from all 7 studies included in the meta-analysis were extracted and analysed using RevMan5.2 soft-ware.
  
  
  RESULTS
  Patients with HBV infection who were undergoing anti-tuberculosis therapy had a higher risk factor than the control patients (OR =5.81, 95% CI =[4.26, 7.39]). The HBV patients with HBeAg positivity who were undergoing anti-tuberculosis therapy had a high risk factor than the HBV patients with HBeAg negativity (OR =2.56, 95% CI=[1.90, 3.44]).
  
  
  CONCLUSIONS
  HBV infection is a risk factor for hepatic lesions when undergoing anti-tuberculosis therapy, and HBeAg-positive status may put a patient at higher risk.
authors.affiliation: Department of Infectious Diseases, Xiangya Hospital of Central South University, Viral hepatitis Key Laboratary of hunan Province, Changsha 410008, China.
authors.forename: Yixiang
authors.initials: Y
authors.lastname: Zheng
authors.forename: Shujuan
authors.initials: S
authors.lastname: Ma
authors.forename: Deming
authors.initials: D
authors.lastname: Tan
authors.forename: Menghou
authors.initials: M
authors.lastname: Lu
mesh_terms: D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006509:Hepatitis B / Q000150:complications / Q000473:pathology*; D006513:Hepatitis B e Antigens / Q000097:blood; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology*; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy / Q000473:pathology*
chemical_list: D000995:Antitubercular Agents; D006513:Hepatitis B e Antigens